Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Policy Pricing Debate

PhRMA Sues To Block 'Unprecedented' California Price Reporting Law

  • News

Executive Summary

Ban on WAC price increases violates Commerce Clause and reporting requirement violates First Amendment, PhRMA contends; complaint says state officials have not clarified whether law is retroactive.

You may also be interested in...



Minnesota's Free Insulin Law Has 'Staggering' Implications, PhRMA Says

PhRMA sues to block implementation of the law, saying it could allow states to compel manufacturers to dispense other medications without compensation.

States Take Center Stage In Tackling Rx Drug Pricing

Dozen drug pricing transparency bills enacted into law over past two years impose different requirements on manufacturers, with a few honing in on PBMs; interactive graphic details these and other pharma-related laws.

Nevada Price Transparency Regs Have Trade Secret Safeguards; Industry Drops Lawsuit

Regulations allow manufacturers to request that drug production and marketing costs and price contracting information provided to the state be kept confidential.

Table

View full table

Related Content

Pink Sheet
Scrip
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Related Companies

Tags:
BioPharmaceutical Policy Pricing Debate
UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By